GPI

GPI is a bifunctional protein that operates both as a glycolytic enzyme (glucose-6-phosphate isomerase) and as a secreted cytokine, autocrine motility factor (AMF/PGI), that drives tumor cell migration, invasion, and metastasis (PMID:30053149, PMID:26308071). Its motogenic cytokine activity is mechanistically separable from its catalytic isomerase activity: pharmacological inhibitors reduce extracellular GPI/AMF activity, EMT marker content, and migration without affecting lactate production (PMID:24440856). Secreted GPI/AMF signals through its receptor AMFR/gp78 and acts via the MAPK-ERK1/2 cascade to promote invasion, migration, and proliferation, with hypoxia upregulating both ligand and receptor (PMID:30053149, PMID:26308071). Engagement of AMFR additionally triggers an integrin switch, upregulating β3 and downregulating β1 integrin to confer an invasive phenotype (PMID:12067203). GPI/AMF expression is positioned downstream of HER2/heregulin signaling, being transcriptionally induced by heregulin and suppressed by anti-HER2 trastuzumab (PMID:12374700), while its cytokine and enzymatic functions are both inhibited by IGFBP-3, which binds GPI/AMF at the cell surface and blocks its phosphorylation, membrane translocation, and migration-promoting activity (PMID:15059907). Direct physical interaction with the glycolysis-related protein GPD2 has also been detected (PMID:32292350).

1. 2002 Medium

   Established that GPI/AMF expression is governed by upstream oncogenic signaling, placing the cytokine downstream of the HER2/heregulin axis and rationalizing its co-targeting in breast cancer.

   Evidence RT-PCR, Western blot, AMF promoter-reporter assay, and combination inhibitor treatment in HER2-high breast cancer cells

   PMID:12374700

   Open questions at the time

   • Transcription factor mediating heregulin-driven AMF induction not identified
   • Does not address how secreted AMF feeds back on HER2 signaling
2. 2002 Low

   Linked AMFR activation to a downstream cell-surface consequence — integrin switching — showing how the AMF-receptor axis remodels adhesion toward an invasive phenotype rather than driving proliferation.

   Evidence AMF stimulation with flow cytometry for β1/β3 integrins and in vivo spontaneous metastasis models in melanoma cells

   PMID:12067203

   Open questions at the time

   • Integrin switching shown by flow cytometry only; signaling intermediates between AMFR and integrin regulation not defined
   • No direct demonstration that integrin switch is required for metastasis
3. 2004 Medium

   Identified IGFBP-3 as a physical negative regulator of GPI/AMF, establishing that an extracellular binding protein can simultaneously block both its enzymatic and motogenic activities.

   Evidence Cell-surface cross-linking of biotinylated IGFBP-3, streptavidin pulldown, ligand blotting, isomerase activity assay, and migration assay in breast cancer cells

   PMID:15059907

   Open questions at the time

   • Binding interface and stoichiometry of the IGFBP-3/GPI interaction unresolved
   • Mechanism by which IGFBP-3 reduces AMF phosphorylation not defined
4. 2014 Medium

   Demonstrated that the motogenic and glycolytic functions of GPI/AMF are mechanistically separable, showing inhibitors can suppress migration and EMT without affecting glycolytic output.

   Evidence Pharmacological inhibition with erythrose-4-phosphate and 6-phosphogluconate, EMT protein quantification, and migration assays in breast cancer tumor spheroids

   PMID:24440856

   Open questions at the time

   • Molecular basis distinguishing cytokine from catalytic activity not structurally defined
   • EMT transcriptional program downstream of AMF not mapped
5. 2015 Medium

   Placed the cytokine function of GPI/AMF in a defined signaling pathway, showing it drives endometrial carcinoma invasion and metastasis through MAPK-ERK1/2.

   Evidence shRNA knockdown, MEK inhibitor treatment, 3D culture, and mouse metastasis models in endometrial carcinoma

   PMID:26308071

   Open questions at the time

   • Receptor-proximal events coupling AMFR to ERK activation not resolved
   • Does not address tissue-specificity of the proliferation versus invasion balance
6. 2018 Medium

   Showed hypoxia coordinately upregulates GPI/AMF and AMFR and that secreted GPI/AMF drives invasion while suppressing proliferation, distinguishing its autocrine cytokine role from its metabolic role.

   Evidence shRNA knockdown, ELISA for secreted GPI/AMF, migration assays, and orthotopic glioblastoma xenografts

   PMID:30053149

   Open questions at the time

   • Mechanism of hypoxia-driven secretion not defined
   • Molecular basis of the migration/proliferation trade-off unresolved
7. 2020 Low

   Identified a direct protein-protein interaction between GPI and the glycolysis-related protein GPD2 and showed small-molecule (esculetin) binding can suppress GPI-dependent glycolysis.

   Evidence Microscale thermophoresis binding assays, glycolysis rate measurement, and tumor models in HepG2 cells

   PMID:32292350

   Open questions at the time

   • GPI-GPD2 interaction shown by single binding method without reciprocal validation
   • Functional consequence of GPI-GPD2 binding not established

• How the receptor-proximal AMFR signaling complex couples to ERK and integrin remodeling, and what structural features separate GPI's cytokine from its enzymatic activity, remain open.
• No structural model distinguishing the catalytic active site from the motogenic surface
• AMFR signaling intermediates upstream of ERK and integrin switching not mapped
• Regulation of GPI/AMF secretion not mechanistically defined